Your browser doesn't support javascript.
Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method.
Sencanski, Milan; Perovic, Vladimir; Pajovic, Snezana B; Adzic, Miroslav; Paessler, Slobodan; Glisic, Sanja.
  • Sencanski M; Laboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
  • Perovic V; Laboratory of Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences Vinca, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
  • Pajovic SB; Department of Molecular Biology and Endocrinology, VINCA Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
  • Adzic M; Department of Molecular Biology and Endocrinology, VINCA Institute of Nuclear Sciences, National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
  • Paessler S; Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Glisic S; Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
Molecules ; 25(17)2020 Aug 23.
Article in English | MEDLINE | ID: covidwho-727434
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Cysteine Endopeptidases / Viral Nonstructural Proteins / Raltegravir Potassium / Betacoronavirus / Mezlocillin Topics: Vaccines Language: English Journal subject: Biology Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Protease Inhibitors / Cysteine Endopeptidases / Viral Nonstructural Proteins / Raltegravir Potassium / Betacoronavirus / Mezlocillin Topics: Vaccines Language: English Journal subject: Biology Year: 2020 Document Type: Article